CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call and live audio webcast scheduled for November 14, 2022, at 4:30 p.m. Eastern Time. The call will discuss the company's financial results for Q3 2022, which ended on September 30, 2022, along with a business update. CymaBay focuses on developing therapies for liver and chronic diseases, with seladelpar designated as a breakthrough therapy and orphan drug for primary biliary cholangitis. More information is available on their website.

Positive

• CymaBay's seladelpar received breakthrough therapy designation from the FDA.
• Seladelpar also received orphan drug status in both the U.S. and Europe.

Negative

• None.

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2022 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 855-327-6837 from the U.S. and Canada, or 631-891-4304 internationally, Conference ID #10020554. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When will CymaBay release its Q3 2022 financial results?

CymaBay will release its Q3 2022 financial results on November 14, 2022.

What is the focus of CymaBay Therapeutics?

CymaBay Therapeutics focuses on developing therapies for liver and other chronic diseases.

What is seladelpar?

Seladelpar is a first-in-class treatment for primary biliary cholangitis developed by CymaBay.

What designations has seladelpar received?

Seladelpar has received breakthrough therapy designation and orphan drug status from the FDA and EMA.